Analgesia in ICU

Quick Answer

Analgesia in ICU requires systematic assessment using validated tools (BPS, CPOT) in non-communicative patients, followed by multimodal treatment to minimize opioid-related complications. The analgesia-first sedation strategy (analgosedation) prioritizes pain control before administering sedatives. Opioids remain first-line for non-neuropathic pain, but multimodal approaches incorporating paracetamol, ketamine, and regional techniques reduce opioid requirements and improve outcomes. [1,2,3]

---

CICM Exam Focus

What examiners want to hear:

1. Pain Assessment: "I would use the BPS or CPOT score, validated in non-communicative ICU patients, with a threshold of greater than 5 (BPS) or ≥3 (CPOT) indicating significant pain requiring treatment." [4,5]

2. Analgesia-First Strategy: "I would adopt an analgosedation approach—treat pain first with adequate analgesia before adding sedation, which reduces total sedative requirements and improves delirium outcomes." [2]

3. Opioid Selection: "For a patient with renal failure requiring frequent neurological assessments, I would choose remifentanil due to its organ-independent metabolism via plasma esterases and ultra-short duration of action." [6,7]

4. Multimodal Approach: "I would use paracetamol 1g IV QID as a baseline, add low-dose ketamine infusion 0.1-0.5 mg/kg/hr for opioid-sparing effect, and consider regional techniques such as thoracic epidural in post-thoracotomy patients." [8,9,10]

5. Safety Monitoring: "I would monitor for opioid-induced complications including respiratory depression, ileus, delirium, and opioid-induced hyperalgesia, particularly with prolonged high-dose infusions." [11]

---

Key Points

• Pain is undertreated in 50-60% of ICU patients despite being present in 70-80% [12,13]
• BPS and CPOT are the most valid behavioral pain scales for non-communicative patients [4,5]
• Self-report remains gold standard when patients can communicate (NRS 0-10) [2]
• Analgosedation reduces ventilator days, delirium, and ICU length of stay [14,15]
• Opioids are first-line for non-neuropathic pain in ICU [2]
• Remifentanil offers organ-independent metabolism, ideal for renal/hepatic failure [6,7]
• Fentanyl accumulates in adipose tissue with prolonged infusions, causing delayed awakening [16]
• Morphine metabolites (M6G) accumulate in renal failure, causing prolonged sedation [17]
• Multimodal analgesia reduces opioid consumption by 20-30% [8,18]
• Ketamine 0.1-0.5 mg/kg/hr provides opioid-sparing analgesia without respiratory depression [9,19]
• Paracetamol 1g IV QID reduces opioid requirements by 15-25% [20,21]
• Regional techniques (epidural, paravertebral, TAP blocks) superior for thoracic/abdominal surgery [22,23]
• NSAIDs must be used cautiously due to renal, cardiovascular, and GI risks [24]
• Gabapentinoids effective for neuropathic pain and post-surgical hyperalgesia [25,26]
• Pre-emptive analgesia for procedures (turning, chest drain removal, dressings) [2,27]

---

Clinical Overview

Epidemiology of Pain in ICU

Pain is highly prevalent in critically ill patients:

• 70-80% of ICU patients experience significant pain during their stay [12,13]
• 50-60% have pain at rest; 80-90% during procedures or nursing care [28]
• 50-60% of patients receive inadequate analgesia despite pain being present [13]
• Pain is associated with increased rates of delirium, PTSD, and chronic pain syndromes [29,30]

Common sources of pain in ICU:

• Surgical wounds (post-operative patients)
• Invasive devices (endotracheal tubes, drains, catheters, lines)
• Procedures (turning, suctioning, physiotherapy, dressing changes)
• Prolonged immobility (pressure areas, contractures)
• Pre-existing conditions (arthritis, neuropathy, malignancy)
• Critical illness complications (ischemia, compartment syndrome)

---

The Analgesia-First (Analgosedation) Paradigm

The 2018 PADIS Guidelines (Pain, Agitation/Sedation, Delirium, Immobility, Sleep) emphasize a shift from sedation-first to analgesia-first strategies. [2]

Rationale:

1. Pain drives agitation: Untreated pain is a major cause of agitation, requiring higher sedative doses
2. Sedation masks pain: Deep sedation prevents pain assessment and recognition
3. Sedatives don't treat pain: Propofol, benzodiazepines, and dexmedetomidine have no analgesic properties
4. Outcomes improve: Analgosedation reduces delirium, ventilator days, and ICU length of stay [14,15]

The e-A-F Bundle: [2]

• A: Assess, Prevent, and Manage Pain — Use validated tools, treat pain routinely
• Analgesia-First: Optimize analgesia before escalating sedation
• F: Facilitate early mobilization and family engagement

---

Pain Assessment in ICU

Self-Report: The Gold Standard

In patients who can communicate, use numerical rating scales (NRS 0-10) or verbal descriptor scales. [2]

• NRS 0: No pain
• NRS 1-3: Mild pain
• NRS 4-6: Moderate pain
• NRS 7-10: Severe pain

Treatment threshold: NRS ≥4 warrants intervention. [2]

---

Behavioral Pain Scales: Non-Communicative Patients

For intubated, sedated, or unconscious patients unable to self-report, behavioral scales are recommended. [4,5]

Behavioral Pain Scale (BPS)

Validated in mechanically ventilated ICU patients. [31]

Total Score: 3-12

• 3: No pain
• 4-5: Mild pain
• 6-8: Moderate pain (consider treatment)
• 9-12: Severe pain (requires treatment)

Cut-off: BPS greater than 5 indicates significant pain requiring intervention. [31]

---

Critical-Care Pain Observation Tool (CPOT)

Validated in both intubated and non-intubated ICU patients. [4,5,32]

Total Score: 0-8

• 0-2: No significant pain
• ≥3: Significant pain (requires treatment)

Cut-off: CPOT ≥3 indicates clinically significant pain. [4,32]

---

Vital Signs Are NOT Reliable Indicators

Heart rate, blood pressure, and respiratory rate are non-specific and influenced by multiple factors (sepsis, hypovolemia, sedation, vasopressors). They should not be used as sole indicators of pain. [2,33]

---

Assessment Frequency

PADIS Guidelines recommend: [2]

• Routine pain assessment at least every 4 hours and after any intervention
• More frequent assessment during painful procedures (turning, suctioning, physiotherapy)
• Document pain scores in the medical record to guide titration

---

Pharmacological Management

First-Line: Opioids

Opioids remain the first-line treatment for moderate-to-severe non-neuropathic pain in ICU patients. [2]

Mechanism: μ-opioid receptor agonists in the CNS and peripheral tissues, inhibiting nociceptive transmission.

---

Fentanyl

Characteristics:

• Onset: 1-2 minutes (IV bolus)
• Duration: 30-60 minutes (single dose); accumulates with infusions
• Potency: 80-100x morphine
• Metabolism: Hepatic (CYP3A4)
• Lipophilicity: Highly lipophilic → distributes into adipose tissue [16]

Clinical Considerations:

• Context-sensitive half-time increases significantly with prolonged infusions (greater than 12-24 hours) due to adipose accumulation [16]
• Delayed awakening common after prolonged infusions, especially in obese patients
• Less histamine release than morphine → hemodynamically more stable
• Renal failure: Safer than morphine (no active metabolites), but still accumulates with prolonged use

Dosing:

• Bolus: 25-100 mcg IV (0.5-2 mcg/kg)
• Infusion: 25-200 mcg/hr (0.5-3 mcg/kg/hr)

---

Morphine

Characteristics:

• Onset: 5-10 minutes (IV)
• Duration: 3-4 hours
• Metabolism: Hepatic glucuronidation → morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G)
• Excretion: Renal clearance of metabolites [17]

Clinical Considerations:

• M6G accumulation in renal failure → prolonged sedation, respiratory depression [17]
• Histamine release → hypotension, bronchospasm (especially with rapid boluses)
• Renal failure: AVOID or use with extreme caution

Dosing:

• Bolus: 2-5 mg IV (0.05-0.1 mg/kg)
• Infusion: 2-10 mg/hr (0.03-0.15 mg/kg/hr)

---

Remifentanil

Characteristics:

• Onset: 1 minute
• Duration: 5-10 minutes (ultra-short acting)
• Metabolism: Plasma and tissue esterases (organ-independent) [6,7]
• Half-life: 3-10 minutes (unchanged by renal or hepatic failure)

Clinical Considerations:

• Organ-independent metabolism: Ideal for renal or hepatic failure [6,7]
• Rapid offset: Enables frequent neurological assessments (neuro ICU, post-neurosurgery)
• No accumulation: Context-sensitive half-time remains constant regardless of infusion duration [34]
• Hyperalgesia risk: Prolonged high-dose use associated with opioid-induced hyperalgesia [11,35]
• Acute tolerance: Rapid development with continuous infusions
• Requires continuous infusion: Cannot be given as intermittent boluses alone

Dosing:

• Infusion: 0.05-0.2 mcg/kg/min (3-12 mcg/kg/hr)
• Titrate to pain scores; typically 0.1 mcg/kg/min starting dose

Indications in ICU:

• Renal or hepatic failure
• Need for frequent neurological assessments (stroke, TBI, post-craniotomy)
• Short-term analgesia for procedures

---

Hydromorphone

Characteristics:

• Potency: 5-7x morphine
• Metabolism: Hepatic glucuronidation → hydromorphone-3-glucuronide (H3G)
• Excretion: Renal

Clinical Considerations:

• Less histamine release than morphine
• H3G accumulation in renal failure (neurotoxic; seizures, myoclonus) [36]
• Used as alternative to morphine in patients with histamine-related hypotension

Dosing:

• Bolus: 0.5-1 mg IV (0.01-0.02 mg/kg)
• Infusion: 0.5-3 mg/hr

---

Opioid-Related Complications

Common side effects:

1. Respiratory depression (dose-dependent; monitor SpO₂, RR, EtCO₂)
2. Sedation (may require reduction if over-sedated)
3. Ileus (delayed gastric emptying, constipation)
4. Nausea/vomiting (5-HT₃ antagonists, metoclopramide)
5. Urinary retention
6. Pruritus (histamine release with morphine)

Serious complications:

7. Delirium (especially with prolonged use) [29]
8. Opioid-induced hyperalgesia (OIH): Paradoxical increased pain sensitivity with prolonged high-dose opioids [11,35]
9. Tolerance: Increasing doses required for same effect
10. Withdrawal syndrome: Abrupt cessation after greater than 5-7 days → agitation, tachycardia, hypertension

Reversal:

• Naloxone: 40-100 mcg IV boluses (titrate to effect); may precipitate acute withdrawal and severe pain

---

Multimodal Analgesia: Opioid-Sparing Strategies

The PADIS Guidelines strongly recommend multimodal analgesia to reduce opioid requirements and associated complications. [2,8]

Benefits:

• 20-30% reduction in opioid consumption [8,18]
• Lower incidence of opioid side effects (ileus, delirium, respiratory depression)
• Improved pain control
• Faster recovery and mobilization

---

Paracetamol (Acetaminophen)

Mechanism: Central COX inhibition, serotonergic modulation.

Evidence:

• Reduces opioid consumption by 15-25% in post-operative patients [20,21]
• Decreases pain scores by 0.5-1.0 points on NRS [20]
• Well-tolerated with minimal side effects

Dosing:

• 1 g IV every 6 hours (maximum 4 g/day)
• Reduce dose in hepatic impairment (below 50 kg, malnutrition, chronic alcohol use)

Contraindications:

• Severe hepatic impairment (Child-Pugh C)
• Hypersensitivity

Safety:

• Generally safe; monitor for hepatotoxicity with prolonged use or overdose

---

Ketamine

Mechanism: NMDA receptor antagonist; provides analgesia, dissociation, amnesia.

Evidence:

• Opioid-sparing: Low-dose ketamine infusions reduce opioid requirements by 20-40% [9,19,37]
• Prevents hyperalgesia: May prevent or treat opioid-induced hyperalgesia [38]
• No respiratory depression: Safe in spontaneously breathing patients
• Effective in opioid-tolerant patients and those with chronic pain [39]

Dosing:

• Bolus: 0.1-0.5 mg/kg IV
• Infusion: 0.1-0.5 mg/kg/hr (typically 2-10 mg/hr in 70 kg patient)

Indications:

• Post-operative pain (especially thoracic, abdominal surgery)
• Burn patients
• Opioid-tolerant or chronic pain patients
• Adjunct in difficult-to-control pain

Side Effects:

• Psychotomimetic effects (hallucinations, dysphoria) — reduced with low doses and benzodiazepine co-administration
• Hypertension, tachycardia (sympathomimetic)
• Hypersalivation (consider glycopyrrolate)
• Emergence delirium (dose-dependent)

Contraindications:

• Severe cardiovascular disease (uncontrolled hypertension, recent MI)
• Increased intracranial pressure (relative; debated)
• Acute psychosis

---

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism: COX-1 and COX-2 inhibition, reducing prostaglandin synthesis.

Evidence:

• Reduce opioid consumption by 15-30% [40]
• Effective for mild-to-moderate pain and inflammatory conditions

Examples:

• Ketorolac: 10-30 mg IV every 6 hours (max 5 days)
• Ibuprofen: 400-800 mg PO/NG every 6-8 hours
• Diclofenac: 50-75 mg PO/IV every 8-12 hours

Risks in ICU patients: [24]

1. Acute kidney injury (AKI): Reduced renal perfusion (COX-1 inhibition)
2. Gastrointestinal bleeding: Ulceration, perforation
3. Cardiovascular events: MI, stroke (COX-2 inhibitors)
4. Bleeding risk: Platelet dysfunction (COX-1 inhibition)
5. Impaired bone healing (orthopaedic surgery)

Contraindications:

• AKI or CKD (eGFR below 30)
• Active peptic ulcer disease or GI bleeding
• Coagulopathy or thrombocytopenia
• Recent cardiac surgery (24-48 hours)
• Hypersensitivity

Use cautiously in ICU; consider only in low-risk patients with short-term use (below 5 days).

---

Gabapentinoids (Gabapentin, Pregabalin)

Mechanism: α₂δ subunit of voltage-gated calcium channels; reduces excitatory neurotransmitter release.

Evidence:

• Effective for neuropathic pain (diabetic neuropathy, postherpetic neuralgia) [25]
• Reduces post-surgical pain and opioid requirements [26,41]
• Beneficial in chronic pain patients and those at risk of opioid tolerance

Dosing:

• Gabapentin: 300-1200 mg PO/NG TID
• Pregabalin: 75-150 mg PO/NG BID

Indications in ICU:

• Neuropathic pain (critical illness polyneuropathy, diabetic neuropathy)
• Post-thoracotomy, post-cardiac surgery (reduces chronic pain incidence)
• Opioid-tolerant patients

Side Effects:

• Sedation, dizziness
• Peripheral edema
• Confusion (especially in elderly or renal impairment)

Renal dosing required.

---

Dexmedetomidine

Mechanism: Selective α₂-adrenergic agonist; sedative, anxiolytic, mild analgesic properties.

Evidence:

• Opioid-sparing: Reduces opioid requirements by 30-50% when used as adjunct [42,43]
• Maintains respiratory drive: Minimal respiratory depression
• Reduces delirium compared to benzodiazepines [44]

Dosing:

• Infusion: 0.2-1.5 mcg/kg/hr (no loading dose in ICU; reduces hemodynamic side effects)

Analgesic Role:

• Adjunct to opioids (not a replacement)
• Useful in post-cardiac surgery, post-extubation, and weaning sedation

Side Effects:

• Bradycardia, hypotension (dose-dependent; α₂-mediated)
• Biphasic cardiovascular response (initial hypertension with bolus)

Contraindications:

• Heart block (2nd/3rd degree)
• Severe bradycardia (HR below 50)

---

Regional Analgesia Techniques

Regional analgesia provides superior pain control with minimal systemic side effects and is strongly recommended for thoracic, abdominal, and orthopedic surgery. [22,23,45]

---

Neuraxial Analgesia (Epidural, Spinal)

Indications:

• Thoracic surgery: Thoracotomy, esophagectomy, lung resection
• Abdominal surgery: Laparotomy, hepatectomy, pancreatectomy
• Major vascular surgery: Aortic aneurysm repair
• Major orthopedic surgery: Hip/knee arthroplasty, femur fracture

Thoracic Epidural Analgesia (TEA):

Evidence:

• Reduces opioid consumption by 50-70% [22,45]
• Decreases pain scores by 1.5-2.5 points (NRS)
• Improves pulmonary function: Better tidal volumes, cough, secretion clearance [46]
• Reduces respiratory complications (pneumonia, atelectasis) [46]
• Facilitates early mobilization

Catheter Placement:

• Thoracic level (T4-T8) for thoracotomy, upper abdominal surgery
• Lumbar level (L2-L4) for lower abdominal, pelvic, lower limb surgery

Infusion:

• Local anesthetic (bupivacaine 0.1-0.125%, ropivacaine 0.2%) ± low-dose opioid (fentanyl 2-5 mcg/mL)
• Typical rate: 5-15 mL/hr

Complications:

• Hypotension (sympathetic blockade) → require vasopressor support
• Epidural hematoma (rare; 1:10,000-1:200,000) — avoid in coagulopathy, thrombocytopenia (below 80,000), therapeutic anticoagulation
• Epidural abscess (rare; 1:1,000-1:10,000)
• Nerve injury, paralysis (extremely rare)

Contraindications:

• Coagulopathy (INR greater than 1.5, aPTT greater than 1.5x normal, platelets below 80,000)
• Therapeutic anticoagulation (requires cessation per ASRA guidelines)
• Local infection at insertion site
• Patient refusal
• Increased intracranial pressure (lumbar epidural)

---

Peripheral Nerve Blocks

Indications:

• Thoracic surgery: Paravertebral block (PVB), serratus anterior plane (SAP) block
• Abdominal surgery: Transversus abdominis plane (TAP) block, rectus sheath block
• Orthopedic surgery: Femoral nerve block, adductor canal block, interscalene block

Paravertebral Block (PVB):

• Effective for thoracotomy and breast surgery [47]
• Comparable analgesia to thoracic epidural with fewer hemodynamic side effects [47]
• Single-shot or continuous catheter

TAP Block:

• Effective for lower abdominal surgery (appendectomy, hernia repair, cesarean section) [48]
• Blocks T6-L1 dermatomes
• Reduces opioid consumption by 30-40% [48]

Advantages:

• Minimal hemodynamic effects
• Can be used in patients with coagulopathy (contraindication to neuraxial)
• Lower infection risk

Disadvantages:

• Limited duration (12-24 hours for single-shot; requires catheter for prolonged analgesia)
• Narrower coverage compared to epidural

---

Special Considerations

Neuropathic Pain

Characteristics: Burning, shooting, electric-shock pain; allodynia, hyperalgesia.

Causes in ICU:

• Critical illness polyneuropathy/myopathy
• Diabetic neuropathy
• Post-herpetic neuralgia
• Nerve injury (trauma, surgery)

Treatment:

• Gabapentinoids (gabapentin, pregabalin) — first-line [25]
• Tricyclic antidepressants (amitriptyline, nortriptyline) — if oral route available
• SNRIs (duloxetine) — for diabetic neuropathy
• Ketamine — refractory cases [38]
• Opioids less effective for neuropathic pain alone

---

Opioid-Induced Hyperalgesia (OIH)

Definition: Paradoxical increased sensitivity to pain despite escalating opioid doses. [11,35]

Risk Factors:

• High-dose opioid infusions (especially remifentanil, fentanyl)
• Prolonged duration (greater than 3-5 days)
• Rapid dose escalation

Clinical Features:

• Increasing pain despite increasing opioid doses
• Diffuse pain (beyond surgical site)
• Allodynia (pain from non-painful stimuli)

Management:

• Opioid rotation: Switch to different opioid (e.g., fentanyl → morphine)
• Opioid dose reduction (counterintuitive but effective)
• Ketamine infusion (0.1-0.5 mg/kg/hr) — NMDA antagonism [38]
• Multimodal analgesia: Maximize non-opioid agents
• Regional techniques where possible

---

Procedural Analgesia

All painful procedures require pre-emptive analgesia. [2,27]

Common ICU procedures:

• Turning and repositioning
• Chest drain insertion/removal
• Dressing changes (burns, surgical wounds)
• Physiotherapy, mobilization
• Central line insertion
• Tracheostomy care
• Endotracheal suctioning

Pre-procedural analgesia:

• Opioid bolus 5-10 minutes before procedure (fentanyl 25-50 mcg)
• Ketamine bolus 0.1-0.25 mg/kg for very painful procedures (drain removal)
• Local anesthetic infiltration for invasive procedures (chest drain insertion)
• Topical anesthetic (lidocaine gel for urinary catheterization)

Assess pain during and after procedure using BPS/CPOT.

---

Withdrawal Syndrome

Occurs after prolonged opioid use (greater than 5-7 days) if abruptly discontinued. [49]

Clinical Features:

• Autonomic: Tachycardia, hypertension, diaphoresis, mydriasis
• GI: Nausea, vomiting, diarrhea, abdominal cramps
• CNS: Agitation, restlessness, insomnia, tremor
• Pain: Myalgias, arthralgias

Prevention:

• Gradual weaning: Reduce opioid dose by 10-20% per day
• Clonidine: α₂-agonist; reduces autonomic symptoms (0.1-0.3 mg PO/NG TID)
• Gabapentin: Reduces withdrawal symptoms

Treatment of acute withdrawal:

• Reinstitute opioid at lower dose, then wean gradually
• Clonidine for autonomic symptoms
• Benzodiazepines for agitation (lorazepam 1-2 mg IV)

---

Monitoring and Titration

Target Pain Scores

• Goal: BPS ≤5, CPOT below 3, NRS below 4 [2]
• Balance analgesia with avoiding over-sedation (target RASS -1 to 0)

---

Frequency of Assessment

• Every 4 hours minimum (routine)
• During/after procedures (turning, suctioning)
• After analgesic intervention (30-60 minutes)

---

Documentation

• Record pain scores in ICU flow chart
• Document analgesic interventions and response
• Communicate pain management plan during handover

---

Titration Principles

1. Start with adequate dose based on severity
2. Titrate to pain score (not vital signs)
3. Use multimodal approach to reduce opioid requirements
4. Anticipate tolerance with prolonged opioid use (may require dose escalation or rotation)
5. Plan weaning strategy early (avoid abrupt cessation)

---

PADIS Guidelines Summary

The 2018 PADIS Guidelines provide evidence-based recommendations for pain management in ICU. [2]

Key Recommendations:

1. Assess pain routinely using validated tools (BPS, CPOT for non-communicative; NRS for communicative patients) — STRONG recommendation
2. Pre-emptive analgesia for all painful procedures — STRONG recommendation
3. Use IV opioids as first-line for non-neuropathic pain — STRONG recommendation
4. Consider non-opioid analgesics (paracetamol, NSAIDs, ketamine) as part of multimodal regimen — CONDITIONAL recommendation
5. Optimize analgesia before sedation (analgosedation approach) — STRONG recommendation
6. Avoid benzodiazepines for routine sedation (preference for propofol or dexmedetomidine) — STRONG recommendation

---

CICM Viva Scenarios

Viva Scenario 1: Post-Operative Pain Management

Stem:

You are the ICU registrar. A 65-year-old man has just arrived in ICU following an emergency laparotomy for perforated diverticulitis. He is intubated and sedated on propofol 150 mg/hr. The nurse asks you to prescribe analgesia. His BPS score is 8.

Model Answer:

Assessment:

"A BPS of 8 indicates significant pain requiring treatment. I would confirm this by checking facial expression, upper limb movements, and ventilator synchrony. I would also assess for other causes of agitation such as hypoxia, hypotension, or delirium."

Analgesia Plan:

"I would adopt a multimodal analgesia approach:

1. Opioid (first-line): Start fentanyl infusion at 50-100 mcg/hr, with 25-50 mcg boluses PRN. I'd titrate to BPS ≤5.
2. Paracetamol: 1 g IV every 6 hours as baseline non-opioid analgesia.
3. Ketamine: Consider low-dose ketamine infusion (0.1-0.2 mg/kg/hr) for opioid-sparing effect, especially if difficult pain or high opioid requirements.
4. Regional technique: Given this is major abdominal surgery, I would consider requesting an epidural catheter (if no coagulopathy) or a TAP block for superior analgesia and reduced opioid needs."

Monitoring:

"I would reassess BPS every 4 hours and after any intervention. I'd monitor for opioid side effects including respiratory depression (though he's mechanically ventilated), ileus, nausea, and oversedation. I'd aim to reduce propofol sedation once analgesia is optimized, using an analgesia-first approach."

Examiner Follow-Up:

Q: "His creatinine is 280 μmol/L. Would you change your opioid choice?"

A: "Yes. Given his acute kidney injury, I would avoid morphine due to accumulation of the active metabolite M6G, which can cause prolonged sedation and respiratory depression. Fentanyl is a reasonable choice as it has no active metabolites, though it may still accumulate with prolonged infusions. If he required frequent neurological assessments, I would consider remifentanil due to its organ-independent metabolism via plasma esterases, though this is less common in general ICU patients."

Q: "What are the contraindications to epidural analgesia in this patient?"

A: "I would check for:

• Coagulopathy: INR, aPTT, platelet count (need platelets greater than 80,000, INR below 1.5)
• Sepsis: He has peritonitis; epidural carries infection risk, though not an absolute contraindication if source-controlled
• Hemodynamic instability: Epidural causes sympathetic blockade and hypotension; would require vasopressor support
• Anticoagulation: Check if on therapeutic anticoagulation (requires cessation per ASRA guidelines)
• Consent: May be difficult post-operatively if patient was emergency

Given his AKI and likely sepsis, I would likely opt for a TAP block instead, which provides good abdominal wall analgesia without hemodynamic effects."

---

Viva Scenario 2: Difficult Pain in Trauma Patient

Stem:

A 32-year-old man is in ICU Day 4 following polytrauma (rib fractures, pulmonary contusions, femur fracture). He is extubated and complaining of severe pain (NRS 9/10) despite fentanyl 150 mcg/hr. He is increasingly agitated and requesting more analgesia.

Model Answer:

Assessment:

"This is a complex pain scenario. I would first assess:

1. Pain characteristics: Location, quality (sharp, aching, burning), exacerbating factors. Rib pain is typically sharp, pleuritic; neuropathic pain would be burning or shooting.
2. Current analgesia adequacy: 150 mcg/hr fentanyl is a substantial dose; inadequate pain control may suggest tolerance, opioid-induced hyperalgesia, or unaddressed pain sources.
3. Rule out complications: New injury (compartment syndrome, missed fracture), infection, DVT, pulmonary embolism.
4. Previous opioid use: History of chronic pain or opioid tolerance?"

Differential for Refractory Pain:

• Inadequate analgesia (under-dosed)
• Opioid tolerance (chronic user or rapid development)
• Opioid-induced hyperalgesia
• Neuropathic pain component (nerve injury)
• Unrecognized injury or complication
• Psychological component (anxiety, PTSD)

Management:

"I would optimize using a multimodal approach:

1. Regional analgesia (essential):

   • Thoracic epidural (T6-T8) for rib fractures — most effective for chest wall pain [45,46]
   • Alternative: Paravertebral block if epidural contraindicated
   • Femoral nerve block or fascia iliaca block for femur fracture pain

2. Adjunct agents:

   • Paracetamol 1 g IV QID (if not already prescribed)
   • Ketamine infusion 0.1-0.5 mg/kg/hr — beneficial in opioid-tolerant patients and for preventing hyperalgesia [9,38]
   • Gabapentin 300-600 mg TDS — if neuropathic pain component suspected

3. Optimize opioid:

   • Consider opioid rotation (switch fentanyl to hydromorphone or oxycodone) if hyperalgesia suspected
   • Add oral oxycodone for breakthrough pain (5-10 mg PO Q4H PRN) now that he's extubated

4. Non-pharmacological:

   • Physiotherapy, positioning, splinting for rib fractures
   • Psychological support (anxiety management)"

Examiner Follow-Up:

Q: "What is opioid-induced hyperalgesia and how do you manage it?"

A: "Opioid-induced hyperalgesia is a paradoxical state where prolonged or high-dose opioid use leads to increased pain sensitivity. It's mediated by NMDA receptor activation and glial cell activation. Clinically, patients report worsening pain despite escalating opioid doses, often with allodynia and diffuse pain beyond the injury site.

Management includes:

1. Opioid dose reduction (counterintuitive but effective)
2. Opioid rotation to a different agent
3. Ketamine (NMDA antagonist) — 0.1-0.5 mg/kg/hr infusion
4. Multimodal analgesia to allow opioid reduction
5. Regional techniques to minimize systemic opioid use"

---

Viva Scenario 3: Analgesia in Renal Failure

Stem:

A 58-year-old woman with ESRD (end-stage renal disease) on hemodialysis is admitted to ICU with septic shock secondary to pneumonia. She is intubated and requires analgesia for an indwelling chest drain. Her CPOT is 5.

Model Answer:

Assessment:

"CPOT of 5 indicates significant pain requiring treatment. In a patient with ESRD, I need to carefully select analgesics to avoid accumulation and prolonged sedation."

Analgesia Plan:

Opioid Choice:

"I would avoid morphine due to accumulation of the active metabolite morphine-6-glucuronide (M6G), which is renally cleared and causes prolonged sedation and respiratory depression in renal failure. [17]

My preferred options are:

1. Fentanyl: Safer than morphine in renal failure (no active metabolites), though can still accumulate with prolonged infusions due to adipose distribution. I would use a reduced dose (e.g., start 25-50 mcg/hr) and titrate carefully.

2. Remifentanil (ideal): Organ-independent metabolism via plasma esterases, making it the best choice in ESRD. [6,7] Context-sensitive half-time is unchanged. I would start at 0.05-0.1 mcg/kg/min and titrate to CPOT below 3.

3. Hydromorphone: Can be used cautiously, but the metabolite H3G accumulates in renal failure and can cause neurotoxicity (seizures, myoclonus). [36]"

Multimodal Adjuncts:

• Paracetamol 1 g IV QID: Safe in renal failure (no dose adjustment needed for IV)
• Ketamine: Safe in renal failure; consider 0.1-0.2 mg/kg/hr infusion
• Regional technique: If stable and not coagulopathic, consider intercostal nerve block or serratus anterior plane block for chest drain analgesia

Avoid:

• NSAIDs: Contraindicated in renal failure (worsen renal function, bleeding risk)
• Gabapentin/pregabalin: Require significant dose reduction (50-75%) and increase sedation risk

Monitoring:

"I would assess CPOT every 4 hours and after interventions, monitor for over-sedation (RASS score), and adjust doses based on dialysis schedule if intermittent hemodialysis (fentanyl may be partially cleared during dialysis)."

Examiner Follow-Up:

Q: "Why is remifentanil ideal in renal failure?"

A: "Remifentanil is metabolized by non-specific plasma and tissue esterases (not hepatic or renal pathways), making its clearance completely organ-independent. [6,7] Its context-sensitive half-time remains 3-10 minutes regardless of infusion duration or renal/hepatic function. This allows predictable offset and avoids accumulation, making it ideal for patients with ESRD or multi-organ failure. The main limitation is the need for continuous infusion and the risk of hyperalgesia with prolonged use."

---

Viva Scenario 4: Analgesia-First Sedation Strategy

Stem:

You are reviewing a 70-year-old woman in ICU Day 2 post-cardiac surgery (CABG). She is intubated on propofol 200 mg/hr and has a fentanyl infusion at 50 mcg/hr. Her RASS is -3 (moderate sedation). The nurse asks if sedation can be reduced to assess for extubation readiness.

Model Answer:

Assessment:

"This is an opportunity to apply the analgesia-first sedation strategy (analgosedation). The patient is deeply sedated (RASS -3), which may be masking pain and delaying extubation assessment. I would first optimize analgesia before reducing sedation."

Analgesia Optimization:

"Before reducing propofol, I would:

1. Assess pain: Reduce propofol briefly to RASS -1 to 0 and assess CPOT/BPS. If CPOT ≥3 or BPS greater than 5, patient has significant pain.

2. Increase fentanyl: 50 mcg/hr may be insufficient post-cardiac surgery. I would:

   • Give bolus fentanyl 25-50 mcg
   • Increase infusion to 75-100 mcg/hr
   • Reassess pain scores after 30 minutes

3. Add multimodal agents:

   • Paracetamol 1 g IV QID
   • Gabapentin 300 mg BD (PO/NG if feeding) — reduces post-sternotomy pain and chronic pain incidence [26,41]
   • Consider dexmedetomidine (0.2-0.7 mcg/kg/hr) as adjunct sedation with analgesic-sparing properties [42,43]

4. Regional technique: Post-cardiac surgery patients benefit from bilateral paravertebral blocks or intrathecal morphine (done at time of surgery); ensure this was done."

Sedation Weaning:

"Once analgesia is optimized (BPS ≤5, CPOT below 3):

• Reduce propofol gradually in 25-50 mg/hr decrements
• Target RASS -1 to 0 (light sedation to calm and awake)
• Assess for extubation readiness when RASS 0 and hemodynamically stable
• If patient becomes agitated during weaning, reassess pain first before increasing sedation"

Benefits of Analgesia-First Approach:

"The analgosedation strategy has been shown to: [14,15]

• Reduce ventilator days
• Decrease delirium incidence
• Shorten ICU length of stay
• Improve patient comfort and satisfaction
• Facilitate early mobilization"

Examiner Follow-Up:

Q: "What is the role of dexmedetomidine in analgosedation?"

A: "Dexmedetomidine is a selective α₂-adrenergic agonist with sedative, anxiolytic, and mild analgesic properties. [42,43] It provides:

• Opioid-sparing effect: Reduces opioid requirements by 30-50%
• Cooperative sedation: Patients are sedated but easily arousable (RASS -1 to 0)
• Minimal respiratory depression: Maintains spontaneous ventilation
• Reduced delirium: Lower delirium incidence compared to benzodiazepines [44]

It's particularly useful post-cardiac surgery and during extubation weaning phases. Limitations include bradycardia and hypotension (dose-dependent), so I'd start at low doses (0.2-0.4 mcg/kg/hr) and titrate slowly.

Importantly, dexmedetomidine is NOT a substitute for opioids — it's an adjunct. Adequate opioid analgesia must be ensured first."

---

CICM OSCE Stations

OSCE Station 1: Pain Assessment Using CPOT

Scenario:

You are the ICU registrar. Assess the pain level of a 55-year-old intubated patient (Day 1 post-right hemicolectomy) using the Critical-Care Pain Observation Tool (CPOT). The patient is on propofol sedation at RASS -1. The nurse reports the patient has been restless during turning.

Marking Criteria:

Examiner Instructions:

Present the candidate with a clinical vignette or simulated patient with the following CPOT findings:

• Facial Expression: Tense (brow lowering, orbit tightening) = 1
• Body Movements: Restlessness (moving in bed, pulling at tube) = 2
• Muscle Tension: Tense, rigid = 2
• Ventilator Compliance: Coughing but tolerating = 1

Total CPOT = 6 (indicates significant pain requiring treatment)

Expected Intervention:

"This patient has a CPOT of 6, indicating significant pain. I would administer:

• Fentanyl 25-50 mcg IV bolus
• Start fentanyl infusion 50 mcg/hr
• Add paracetamol 1 g IV QID
• Consider TAP block or epidural given major abdominal surgery
• Reassess CPOT in 30 minutes, aiming for CPOT below 3"

---

OSCE Station 2: Prescribing Multimodal Analgesia

Scenario:

You are the ICU registrar. A 45-year-old woman has been admitted following a motor vehicle accident with multiple rib fractures (ribs 4-8 on the left) and a splenic laceration (managed conservatively). She is alert (RASS 0) and reports pain 8/10 on movement. You are asked to prescribe a multimodal analgesia regimen.

Marking Criteria:

Examiner Questions:

Q1: "Why is regional analgesia particularly important in this patient?"

Expected Answer: "This patient has multiple rib fractures, which cause severe pleuritic pain limiting deep breathing, cough, and secretion clearance. This increases the risk of atelectasis and pneumonia. Thoracic epidural analgesia at T6-T8 provides superior analgesia compared to systemic opioids, improves tidal volumes and respiratory mechanics, and reduces pulmonary complications. [45,46] It also reduces opioid requirements by 50-70%, minimizing sedation and ileus."

Q2: "What are the contraindications to epidural in this patient?"

Expected Answer: "I would check:

• Coagulopathy: FBC (platelets greater than 80,000), coagulation profile (INR below 1.5, aPTT below 1.5x normal). Splenic injury may cause ongoing bleeding, increasing risk.
• Hemodynamic stability: Epidural causes sympathetic blockade and hypotension. If she's hypotensive or requiring fluid resuscitation, I would defer until stable.
• Anticoagulation: Check if on therapeutic anticoagulation for VTE prophylaxis (requires cessation per ASRA guidelines).

If epidural is contraindicated, I would use a paravertebral block (provides comparable analgesia with fewer hemodynamic effects) or serratus anterior plane block."

---

OSCE Station 3: Managing Opioid-Induced Hyperalgesia

Scenario:

A 60-year-old man is in ICU Day 7 following emergency AAA repair. He is on fentanyl 200 mcg/hr (increased from 100 mcg/hr on Day 3) and reports worsening abdominal pain (NRS 9/10) despite dose escalation. Pain is diffuse, and he reports hypersensitivity even to light touch. You suspect opioid-induced hyperalgesia.

Marking Criteria:

Examiner Questions:

Q1: "What is the mechanism of opioid-induced hyperalgesia?"

Expected Answer: "OIH is a paradoxical state of increased nociceptive sensitization caused by prolonged or high-dose opioid exposure. Mechanisms include: [11,35]

1. NMDA receptor activation: Opioids activate NMDA receptors in the spinal cord, leading to central sensitization.
2. Glial cell activation: Microglia and astrocytes release pro-inflammatory cytokines (IL-1β, TNF-α), amplifying pain signaling.
3. Descending facilitation: Enhanced descending pain pathways from the brainstem.
4. Dynorphin upregulation: Increased pronociceptive neuropeptides.

Clinically, patients report worsening pain despite escalating opioid doses, allodynia, and pain beyond the original injury site."

Q2: "How does ketamine help in this scenario?"

Expected Answer: "Ketamine is an NMDA receptor antagonist, blocking the central sensitization pathway that drives opioid-induced hyperalgesia. [38] It:

• Reverses NMDA-mediated hyperalgesia
• Provides analgesia without cross-tolerance to opioids
• Has no respiratory depression
• Allows opioid dose reduction while maintaining pain control

I would use a low-dose infusion (0.1-0.5 mg/kg/hr) to minimize psychotomimetic side effects. This is often combined with opioid rotation and multimodal agents."

---

CICM SAQ Practice Questions

SAQ 1: Pain Assessment in Non-Communicative ICU Patients

Question:

A 68-year-old man is intubated and sedated in ICU following emergency CABG surgery. He is on propofol 100 mg/hr (RASS -2) and fentanyl 25 mcg/hr. The bedside nurse reports the patient appears uncomfortable during turning.

a) What validated tools can be used to assess pain in this non-communicative patient? (2 marks)

b) Describe the domains and scoring of the Critical-Care Pain Observation Tool (CPOT). (6 marks)

c) What are the limitations of using vital signs (heart rate, blood pressure) as indicators of pain in ICU patients? (2 marks)

Model Answer:

a) Validated tools for non-communicative patients (2 marks):

• Behavioral Pain Scale (BPS) — validated in mechanically ventilated patients (1 mark)
• Critical-Care Pain Observation Tool (CPOT) — validated in both intubated and non-intubated ICU patients (1 mark)

b) CPOT domains and scoring (6 marks):

The CPOT assesses 4 domains, each scored 0-2: [4,5,32]

1. Facial Expression (0.5 marks for domain, 0.5 marks for scoring):

   • 0 = Relaxed, neutral
   • 1 = Tense (brow lowering, orbit tightening)
   • 2 = Grimacing (eyes closed, nose wrinkling)

2. Body Movements (0.5 marks for domain, 0.5 marks for scoring):

   • 0 = Absence of movements or normal position
   • 1 = Protection (touching pain site, slow movements)
   • 2 = Restlessness (pulling tube, limb thrashing)

3. Muscle Tension (0.5 marks for domain, 0.5 marks for scoring):

   • 0 = Relaxed
   • 1 = Tense, rigid
   • 2 = Very tense or rigid

4. Compliance with Ventilator (intubated) OR Vocalization (extubated) (0.5 marks for domain, 0.5 marks for scoring):

   • 0 = Tolerating ventilator / Talking in normal tone
   • 1 = Coughing but tolerating / Sighing, moaning
   • 2 = Fighting ventilator / Crying out, sobbing

Total score: 0-8 (0.5 marks)

Threshold: CPOT ≥3 indicates clinically significant pain requiring treatment (0.5 marks)

c) Limitations of vital signs (2 marks):

• Vital signs (HR, BP, RR) are non-specific and influenced by multiple factors in ICU patients (1 mark)
• Contributing factors include sepsis, hypovolemia, sedation, vasopressors, beta-blockers, arrhythmias — not necessarily pain (0.5 marks)
• PADIS Guidelines state vital signs should not be used as sole indicators of pain [2,33] (0.5 marks)

---

SAQ 2: Multimodal Analgesia in Post-Operative ICU Patient

Question:

A 55-year-old woman is in ICU Day 1 following Whipple procedure (pancreaticoduodenectomy). She is extubated and alert, reporting pain 7/10. Her medical history includes hypertension and obesity (BMI 38). She is currently on morphine PCA.

a) What are the principles and benefits of multimodal analgesia? (3 marks)

b) List FIVE non-opioid agents/techniques you would use as part of a multimodal regimen in this patient. (5 marks)

c) What is the role of ketamine in multimodal analgesia, including dosing and side effects? (2 marks)

Model Answer:

a) Principles and benefits of multimodal analgesia (3 marks):

Principles:

• Use of multiple analgesic agents with different mechanisms of action to target pain pathways at different sites (peripheral, spinal, supraspinal) (1 mark)
• Allows lower doses of each agent, reducing side effects while maintaining analgesia (0.5 marks)

Benefits:

• 20-30% reduction in opioid consumption [8,18] (0.5 marks)
• Reduced opioid-related side effects (ileus, delirium, respiratory depression, nausea) (0.5 marks)
• Improved pain control and patient satisfaction (0.25 marks)
• Faster recovery and mobilization (0.25 marks)

b) Five non-opioid agents/techniques (5 marks, 1 mark each):

1. Paracetamol (acetaminophen): 1 g IV every 6 hours (reduces opioid consumption by 15-25%) [20,21]

2. Ketamine: Low-dose infusion 0.1-0.5 mg/kg/hr (NMDA antagonist, opioid-sparing by 20-40%) [9,19]

3. Gabapentin or pregabalin: 300-600 mg TDS PO/NG (effective for neuropathic pain, reduces post-surgical hyperalgesia) [25,26]

4. Thoracic epidural analgesia: T6-T8 epidural with local anesthetic ± opioid (superior for major abdominal surgery; reduces opioid needs by 50-70%) [22,45]

   OR Transversus abdominis plane (TAP) block (alternative if epidural contraindicated) [48]

5. Dexmedetomidine: 0.2-0.7 mcg/kg/hr infusion (α₂-agonist; opioid-sparing, reduces delirium) [42,43]

Note: NSAIDs are generally avoided in this patient due to risk of renal impairment (obesity, major surgery) and anastomotic bleeding risk.

c) Role of ketamine (2 marks):

Role:

• NMDA receptor antagonist providing opioid-sparing analgesia (0.5 marks)
• Reduces opioid consumption by 20-40%; prevents/treats opioid-induced hyperalgesia [9,38] (0.5 marks)

Dosing:

• 0.1-0.5 mg/kg/hr IV infusion (typically 2-10 mg/hr in 70 kg patient) (0.5 marks)

Side effects:

• Psychotomimetic effects (hallucinations, dysphoria), hypertension, tachycardia, hypersalivation (0.5 marks)

---

SAQ 3: Opioid Selection in Special Populations

Question:

You are managing analgesia in two ICU patients:

Patient A: 62-year-old man, Day 2 post-craniotomy for subdural hematoma evacuation. Intubated, requires frequent neurological assessments (GCS and pupil checks every hour).

Patient B: 70-year-old woman with ESRD on hemodialysis, admitted with septic shock. Intubated, requiring analgesia for chest drain.

a) What is your opioid of choice for Patient A and why? (2 marks)

b) What opioids should be avoided in Patient B with ESRD, and why? (3 marks)

c) What is your opioid of choice for Patient B and why? (2 marks)

d) Outline THREE non-opioid analgesic strategies suitable for Patient B. (3 marks)

Model Answer:

a) Opioid choice for Patient A (neurosurgery, frequent neuro assessments) (2 marks):

Remifentanil (2 marks)

Rationale:

• Ultra-short duration (half-life 3-10 minutes) allows rapid offset for neurological assessments [6,7,34] (1 mark)
• Organ-independent metabolism via plasma esterases; no accumulation with prolonged infusions (0.5 marks)
• Enables reliable and frequent GCS assessments without prolonged sedation/analgesia clouding clinical exam (0.5 marks)

b) Opioids to avoid in ESRD (Patient B) (3 marks):

1. Morphine (1 mark):

   • Active metabolite morphine-6-glucuronide (M6G) is renally cleared and accumulates in renal failure [17] (0.5 marks)
   • Causes prolonged sedation, respiratory depression, and opioid toxicity (0.5 marks)

2. Hydromorphone (1 mark):

   • Metabolite hydromorphone-3-glucuronide (H3G) accumulates in renal failure [36] (0.5 marks)
   • Neurotoxic effects: seizures, myoclonus, agitation (0.5 marks)

c) Opioid choice for Patient B (ESRD) (2 marks):

Remifentanil (1 mark)

Rationale:

• Organ-independent metabolism via plasma esterases; clearance unaffected by renal or hepatic failure [6,7] (0.5 marks)
• No active metabolites; predictable pharmacokinetics regardless of renal function (0.5 marks)

Alternative acceptable answer: Fentanyl (with caution) — no active metabolites, but may accumulate with prolonged infusions due to adipose distribution; requires dose reduction.

d) Three non-opioid strategies for Patient B (3 marks, 1 mark each):

1. Paracetamol 1 g IV QID: Safe in renal failure (no dose adjustment for IV route); reduces opioid requirements by 15-25% [20,21]

2. Ketamine infusion 0.1-0.5 mg/kg/hr: Safe in renal failure; NMDA antagonist, opioid-sparing, no respiratory depression [9,19]

3. Regional analgesia: Intercostal nerve block, serratus anterior plane (SAP) block, or paravertebral block for chest drain analgesia (if no coagulopathy) [47]

Note: Avoid NSAIDs (contraindicated in renal failure), and gabapentin/pregabalin require significant dose reduction.

---

SAQ 4: Analgesia-First Sedation and PADIS Guidelines

Question:

A 58-year-old man is in ICU Day 3 following emergency bowel resection for ischemic bowel. He is intubated on propofol 150 mg/hr (RASS -2) and fentanyl 50 mcg/hr. You are asked to review his sedation plan with a view to weaning for extubation.

a) What is the analgesia-first sedation strategy (analgosedation), and what are its benefits? (3 marks)

b) Outline your approach to optimizing analgesia before reducing sedation in this patient. (4 marks)

c) What are the PADIS Guidelines key recommendations for pain management in ICU? (3 marks)

Model Answer:

a) Analgesia-first sedation strategy (analgosedation) (3 marks):

Definition:

• Prioritize adequate analgesia before administering or escalating sedative agents (0.5 marks)
• Treat pain as the primary cause of agitation, rather than reflexively increasing sedation (0.5 marks)

Rationale:

• Sedatives (propofol, benzodiazepines) have no analgesic properties; they mask pain without treating it (0.5 marks)
• Untreated pain drives agitation, leading to higher sedation requirements (0.5 marks)

Benefits: [14,15]

• Reduced ventilator days (0.25 marks)
• Reduced delirium incidence (0.25 marks)
• Shorter ICU length of stay (0.25 marks)
• Improved patient comfort and facilitates early mobilization (0.25 marks)

b) Approach to optimizing analgesia before reducing sedation (4 marks):

Step 1: Assess pain (1 mark)

• Reduce propofol briefly to achieve RASS -1 to 0 (0.5 marks)
• Assess pain using BPS or CPOT (non-communicative patient); threshold BPS greater than 5 or CPOT ≥3 indicates significant pain (0.5 marks)

Step 2: Optimize opioid analgesia (1 mark)

• Bolus fentanyl 25-50 mcg IV (0.25 marks)
• Increase fentanyl infusion to 75-100 mcg/hr (0.25 marks)
• Reassess pain scores 30 minutes after intervention (0.25 marks)
• Consider opioid rotation if inadequate response (0.25 marks)

Step 3: Add multimodal agents (1.5 marks)

• Paracetamol 1 g IV QID (0.5 marks)
• Ketamine infusion 0.1-0.5 mg/kg/hr for opioid-sparing effect (0.5 marks)
• Regional technique (epidural or TAP block) if appropriate for major abdominal surgery (0.5 marks)

Step 4: Reduce sedation once analgesia optimized (0.5 marks)

• Gradually reduce propofol by 25-50 mg/hr decrements, targeting RASS -1 to 0 (0.25 marks)
• If agitation occurs, reassess pain first before increasing sedation (0.25 marks)

c) PADIS Guidelines key recommendations for pain (3 marks):

The 2018 PADIS Guidelines recommend: [2]

1. Routine pain assessment using validated tools (BPS/CPOT for non-communicative; NRS for communicative patients) — at least every 4 hours (1 mark)

2. Pre-emptive analgesia for all painful procedures (turning, suctioning, dressing changes, drains) (1 mark)

3. IV opioids as first-line for non-neuropathic pain; multimodal analgesia (paracetamol, ketamine, regional techniques) to reduce opioid requirements (1 mark)

Bonus: Analgesia-first sedation (analgosedation) to optimize analgesia before escalating sedation.

---

References

1. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306. PMID: 23269131
2. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. PMID: 30113379
3. Erstad BL, Puntillo K, Gilbert HC, et al. Pain management principles in the critically ill. Chest. 2009;135(4):1075-1086. PMID: 19349396
4. Gélinas C, Fillion L, Puntillo KA, et al. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420-427. PMID: 16823021
5. Payen JF, Bru O, Bosson JL, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001;29(12):2258-2263. PMID: 11801819
6. Breen D, Wilmer A, Bodenham A, et al. Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care. 2004;8(1):R21-R30. PMID: 14975050
7. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology. 1998;89(3):562-573. PMID: 9743391
8. Grape S, Ravussin P. Multimodal analgesia in day surgery. Best Pract Res Clin Anaesthesiol. 2013;27(2):235-255. PMID: 24012235
9. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357-367. PMID: 23432384
10. Blaudszun G, Lysakowski C, Elia N, Tramèr MR. Effect of perioperative systemic α2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312-1322. PMID: 22546966
11. Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161. PMID: 21412369
12. Puntillo KA, White C, Morris AB, et al. Patients' perceptions and responses to procedural pain: results from Thunder Project II. Am J Crit Care. 2001;10(4):238-251. PMID: 11432212
13. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med. 2006;34(6):1691-1699. PMID: 16625136
14. Strøm T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet. 2010;375(9713):475-480. PMID: 20116842
15. Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012;186(8):724-731. PMID: 22859526
16. Shafer SL. Shock values. Anesthesiology. 2004;101(3):567-568. PMID: 15329578
17. Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol. 1990;38(2):121-124. PMID: 2338107
18. Elia N, Lysakowski C, Tramèr MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology. 2005;103(6):1296-1304. PMID: 16306743
19. Guillou N, Tanguy M, Seguin P, et al. The effects of small-dose ketamine on morphine consumption in surgical intensive care unit patients after major abdominal surgery. Anesth Analg. 2003;97(3):843-847. PMID: 12933415
20. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth. 2005;94(4):505-513. PMID: 15681586
21. Tzortzopoulou A, McNicol ED, Cepeda MS, et al. Single dose intravenous propacetamol or intravenous paracetamol for postoperative pain. Cochrane Database Syst Rev. 2011;(10):CD007126. PMID: 21975768
22. Block BM, Liu SS, Rowlingson AJ, et al. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA. 2003;290(18):2455-2463. PMID: 14612482
23. Joshi GP, Bonnet F, Shah R, et al. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg. 2008;107(3):1026-1040. PMID: 18713924
24. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. PMID: 10390124
25. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173. PMID: 25575710
26. Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg. 2012;115(2):428-442. PMID: 22415535
27. Puntillo KA, Morris AB, Thompson CL, et al. Pain behaviors observed during six common procedures: results from Thunder Project II. Crit Care Med. 2004;32(2):421-427. PMID: 14758158
28. Arroyo-Novoa CM, Figueroa-Ramos MI, Puntillo KA, et al. Pain related to tracheal suctioning in awake acutely and critically ill adults: a descriptive study. Intensive Crit Care Nurs. 2008;24(1):20-27. PMID: 17689249
29. Schelling G, Stoll C, Haller M, et al. Health-related quality of life and posttraumatic stress disorder in survivors of the acute respiratory distress syndrome. Crit Care Med. 1998;26(4):651-659. PMID: 9559601
30. Battle CE, Lovett S, Hutchings H. Chronic pain in survivors of critical illness: a retrospective analysis of incidence and risk factors. Crit Care. 2013;17(3):R101. PMID: 23718685
31. Payen JF, Bosson JL, Chanques G, et al. Pain assessment is associated with decreased duration of mechanical ventilation in the intensive care unit: a post hoc analysis of the DOLOREA study. Anesthesiology. 2009;111(6):1308-1316. PMID: 19934877
32. Gélinas C. Pain assessment in the critically ill adult: Recent evidence and new trends. Intensive Crit Care Nurs. 2016;34:1-11. PMID: 26943181
33. Aïssaoui Y, Zeggwagh AA, Zekraoui A, et al. Validation of a behavioral pain scale in critically ill, sedated, and mechanically ventilated patients. Anesth Analg. 2005;101(5):1470-1476. PMID: 16244013
34. Kapila A, Glass PS, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83(5):968-975. PMID: 7486182
35. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570-587. PMID: 16508405
36. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27(7):524-528. PMID: 10874511
37. Blonk MI, Koder BG, van den Bemt PM, Huygen FJ. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2010;14(5):466-472. PMID: 19879174
38. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth. 2011;58(10):911-923. PMID: 21773855
39. Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456-466. PMID: 29794322
40. Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005;102(6):1249-1260. PMID: 15915040
41. Fassoulaki A, Melemeni A, Staikou C, et al. Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. Eur J Anaesthesiol. 2012;29(11):531-536. PMID: 22968289
42. Ren J, Zhang H, Huang L, et al. Protective effect of dexmedetomidine in coronary artery bypass grafting surgery. Exp Ther Med. 2013;6(2):497-502. PMID: 24137215
43. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499. PMID: 19188334
44. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-2653. PMID: 18073360
45. Joshi GP, Bonnet F, Shah R, et al. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg. 2008;107(3):1026-1040. PMID: 18713924
46. Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized, controlled trials. Anesth Analg. 1998;86(3):598-612. PMID: 9495424
47. Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy--a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2006;96(4):418-426. PMID: 16476698
48. Abdallah FW, Laffey JG, Halpern SH, Brull R. Duration of analgesic effectiveness after the posterior and lateral transversus abdominis plane block techniques for transverse lower abdominal incisions: a meta-analysis. Br J Anaesth. 2013;111(5):721-735. PMID: 23811424
49. Cammarano WB, Pittet JF, Weitz S, et al. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998;26(4):676-684. PMID: 9559604

---

Metadata

Topic: Analgesia in ICU
Specialty: Intensive Care
Category: Sedation
Target Exam: CICM Second Part Examination
Difficulty: Moderate
Lines: 1,504
Citations: 38 PubMed references
Last Updated: 2026-01-24

---

Tags

#CICM #IntensiveCare #Analgesia #PainManagement #Opioids #MultimodalAnalgesia #Analgosedation #BPS #CPOT #PADISGuidelines #Remifentanil #Fentanyl #Ketamine #RegionalAnalgesia #OpioidInducedHyperalgesia